| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328287 | Acta Haematologica Polonica | 2014 | 5 Pages |
Abstract
Acute myeloid leukaemia (AML) is a neoplasm originating in early haematopoietic progenitor cells. Each AML clone contains a subpopulation of leukaemic stem cells (LSCs). LSCs have the capacity to repopulate AML in NOD/SCID mice and regrow leukaemia in patients after remission period. LSCs are characterized by CD34+CD38-Lin-CD33+/-CD123+ immunophenotype. The currently available data show that LSCs play a pivotal role in drug resistance. Many studies and clinical trials are being conducted to eradicate LSCs using different forms of target therapy.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Maria Cioch, Karolina Radomska,